Is Immuneering Corp (IMRX) overvalued? · $124.2M cap
Immuneering Corp (IMRX) is a biotechnology company listed on US.
This page asks whether Immuneering Corp (IMRX) looks expensive on cached numbers — not a short thesis.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
IMRX currently screens at market cap $124.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IMRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IMRX stock page for the full model, not this heading.
Not investment advice.